• Myeloma UK
  • Clinical Service Excellence Programme
Top menu
TwitterFacebook
Myeloma Academy
Myeloma Academy

Sign in | Register

Call us for more info on 0131 557 3332

Menu
  • Home
  • CPD & Learning
    • Myeloma Nurse Learning Programme
    • My CPD Portfolio
    • Challenging Cases
    • Close
  • Library
    • Guidelines
      • Complications
      • COVID-19 guidance
      • General haemato/oncology
      • Imaging & Analysis
      • Management & Treatment
      • Palliative Care
      • Presentation & Diagnosis
      • Related conditions
      • Close
    • Patient Support and Information
    • Medical animations
    • Close
  • Resources
    • Myeloma Drug Finder
    • Myeloma Trial Finder
    • Assessment tools
    • Myeloma Spotlight
    • Primary care education
    • Secondary care education
    • Myeloma health economic model
    • Close
  • News & Events
    • News
    • Event calendar
    • Meeting highlights
    • Close
  • CSEP
  • About Us
    • Contact Us
    • Close
MENU CLOSE back  

Imaging & Analysis

IMWG consensus recommedations on imaging in monoclonal plasma cell disorders

The IMWG present recommendations on imaging both in clinical practice and in the trial setting to help standardise the best imaging methods to use as myeloma patients progress through different disease stages.

Read article

June 1, 2019

Guidelines for Acquisition, Interpretation, and Reporting of Whole-Body MRI in Myeloma: Myeloma Response Assessment and Diagnosis System (MY-RADS)

As whole-body MRI is listed in NICE guidance as the recommended first line imaging in patients with suspected myeloma, this paper outlines a clinical protocol: the Myeloma Response Assessment and Diagnosis System (MY-RADS), for its use and interpretation.

Read article

February 26, 2019

Recommendations for acquisition, interpretation and reporting of whole body low dose CT in patients with multiple myeloma and other plasma cell disorders: a report of the IMWG Bone Working Group

The Bone group of the IMWG present recommendations for the use of whole body low-dose CT in patients with myeloma and other plasma cell disorders, as an imaging method for assessing bone disease in these patients.

Read article

October 8, 2018

IMWG Consensus criteria for response and minimal residual disease in myeloma

This paper, produced by an expert panel of the International Myeloma Working Group (IMWG) reviews the assessment of disease response and endpoints for clinical trials, and provides updated response categories of minimal residual disease negativity.

Read abstract

November 2, 2017

Guidelines for the use of imaging in the management of patients with myeloma

These updated guidelines, produced by the British Society of Haematology and Myeloma UK summarise a national consensus for the use of imaging in the diagnosis and management of myeloma patients.

Chantry et al. (2017) British Journal of Haematology

July 31, 2017
Download

IMWG Consensus statement on the role of 18F-FDG PET/CT in the diagnosis and management of myeloma and related diseases

This paper, written by the International Myeloma Working Group (IMWG), reviews the current evidence, and provides recommendations for the optimal use of  18F-FDG PET/CT in the diagnosis and management of multiple myeloma and related diseases, including smouldering myeloma and solitary plasmacytoma.

Read article

April 1, 2017

IMWG Guidelines for serum free light chain analysis in multiple myeloma and related disorders

This paper, written by an expert panel on behalf of the International Myeloma Working Group, provides consensus guidelines for the use of the serum free light chain assay in the diagnosis and management of clonal plasma cell disorders.

August 7, 2014
Download
  • Guidelines
    • Complications
    • COVID-19 guidance
    • General haemato/oncology
    • Imaging & Analysis
    • Management & Treatment
    • Palliative Care
    • Presentation & Diagnosis
    • Related conditions
  • Patient Support and Information
  • Medical animations
Myeloma Academy
Bottom menu

Registered Charity
No. SC 026116
Myeloma UK
22 Logie Mill
Beaverbank Business Park
Edinburgh
EH7 4HG